Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: David Jones who wrote (1333)	7/21/1998 3:56:00 PM
From: admr	Read Replies (2) \| Respond to of 4140

First time posting. There was a negative comment on Dow Jones under Visx noting that the use of the laser will not be that significant in hyperopia. The analyst name is Lachman. He notes that in Europe and Canada where the procedure is already approved it makes up only 10 to 30% of the market. He also notes that older people are more conservative than younger myopic patients and they just need reading glasses. Of course he is talking abount the excimer laser and maybe because of the procedure itself it's not used that much. If a safe, noninvasive, fairly priced procedure with good results is available it will sell to the hyperopic and presbyopic patient.